Member Contact: Mark Ziirsen
Position: Chief Financial Officer
Industry: Medtech & Digital
Admedus is a diversified healthcare company focused on Investing in next generation technologies with world class partners, Acquiring strategic assets to grow its product and service offerings and Expanding revenue from its existing medical sales and distribution businesses.
Admedus has assets from Research & Development through to Sales, Marketing and Distribution
• R&D – our lead investment in Professor Ian Frazer’s vaccine technology is targeting HSV2 and HPV and has both preventative and therapeutic properties that can be applied to a range of infectious diseases and cancers.
• Commercialisation – Admedus is using its proprietary tissue engineering process ADAPT® to develop a range of products for soft tissue repair in the human body. The first product, CardioCel®, is on the market for the repair and reconstruction of congenital heart deformities and more complex heart defects.
• Sales and Distribution – expansion and growth by acquisition will enable the distribution arm of the company to expand from its Australian footprint as a global provider of our own and third party medical devices and consumables